Janux Therapeutics (JANX) Current Deferred Revenue (2020 - 2026)

Janux Therapeutics (JANX) has reported Current Deferred Revenue for 6 consecutive years, with $37.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $37.6 million; the TTM figure through Mar 2026 stood at $37.6 million (changed N/A YoY), while the FY2023 annual figure was $1.7 million, down 68.46% from the prior year.
• Current Deferred Revenue improved to $37.6 million in Q1 2026 per JANX's latest filing, from $94000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $37.6 million in Q1 2026 and bottomed at $94000.0 in Q2 2024.
• Historically, Current Deferred Revenue has averaged $6.9 million across 4 years, with a median of $4.9 million in 2023.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue grew 12.2% — and 2024, when it tumbled 98.24%.
• Janux Therapeutics' Current Deferred Revenue stood at $5.4 million in 2022, then plunged by 68.46% to $1.7 million in 2023, then plunged by 94.49% to $94000.0 in 2024, then soared by 39890.43% to $37.6 million in 2026.
• Business Quant data shows JANX's Current Deferred Revenue at $37.6 million in Q1 2026, $94000.0 in Q2 2024, and $972000.0 in Q1 2024.